A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab is a research paper published in Cancer Discovery (2021). On theSindex it has a DataRank of 0.954. It has been cited 578 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.954
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: P30 CA008748
NIH
Grant: R01 CA236615-01
NIH
Grant: R01 CA235667
U.S. Department of Defense
Grant: BC132124
U.S. Department of Defense
Grant: LC160212
U.S. Department of Defense
Grant: CA180889
NCI NIH HHS
Grant: R01 CA217169
NCI NIH HHS
Grant: R01 CA236615
National Institutes of Health
Grant: 5R01CA236615-02
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5R01CA235667-02
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
FWCI
29.81
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals